Phase II California Cancer Consortium Trial of Gemcitabine-Eribulin Combination in Cisplatin-Ineligible Patients With Metastatic Urothelial Carcinoma: Final Report (NCI-9653)

Sarmad Sadeghi,Susan Groshen,Denice D. Tsao-Wei,Rahul Atul Parikh,Amir Mortazavi,Tanya B. Dorff,Cheryl Kefauver,Christopher J. Hoimes,Laurence A. Doyle,David I. Quinn,Edward M. Newman,Primo N. Lara

Phase II California Cancer Consortium Trial of Gemcitabine-Eribulin Combination in Cisplatin-Ineligible Patients With Metastatic Urothelial Carcinoma: Final Report (NCI-9653)

2019

Sarmad Sadeghi
Susan Groshen
Denice D. Tsao-Wei
Rahul Atul Parikh
Amir Mortazavi
Tanya B. Dorff
Cheryl Kefauver
Christopher J. Hoimes
Laurence A. Doyle
David I. Quinn
Edward M. Newman
Primo N. Lara

PURPOSEPatients with metastatic urothelial carcinoma are often ineligible for cisplatin-based treatments. A National Cancer Institute Cancer Therapy Evaluation Program–sponsored trial assessed the ...

Keywords:

Eribulin
Cancer
Therapy Evaluation
Gemcitabine
Cisplatin
Pathology
Metastatic Urothelial Carcinoma
Oncology
Internal medicine
Medicine
cancer therapy

Correction
Source
Cite
Save
Machine Reading By IdeaReader

References

Citations